Clinical Trial

Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

Study acronym: ZQL008
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and skeletal muscle microvascular blood volume, improves vascular function of the conduit vessels, and enhances insulin's metabolic action in humans with Metabolic Syndrome. Subjects will be randomized to one of the 4 groups: control, exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 24 weeks of intervention.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-09-30; most recent amendment 2026-05-01.
Status change: Not Yet Recruiting → Recruiting 2021-03-10
Trial Details
NCT Number NCT04575844
Lead Sponsor University of Virginia
Collaborators: National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Metabolic Syndrome
Enrollment 80 participants
Start Date 2020-11-01
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-06